3 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: September 19, 2022
Myocardial perfusion, also known as a "stress test", is today's go-to-method for detecting coronary artery disease - despite limited performance.
Read More »7 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: August 1, 2022
The current approach to cardiovascular care is flawed for two reasons. One is the lack of a disease-based care paradigm with a focus on actual heart disease–atherosclerosis– in lieu of an emphasis on symptom-driven care that identifies only late-stage...
3 min read
Last week, our team at Cleerly had the opportunity to take part in a gathering of impassioned cardiac computed tomography (CT) leaders at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Las Vegas. As the former...
3 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: April 15, 2022
New research proposes a four-stage system for measuring the progression of cardiovascular disease (CAD) based on atherosclerotic plaque - not secondary symptoms of heart disease.
4 min read
Cleerly is excited to have released our vision statement calling for a new approach to cardiovascular care. It's an important topic - not just for Cleerly, but for the healthcare industry and all the patients impacted by heart disease - and we're going...
4 min read
Cleerly is excited to have released our vision statement calling for a new approach to cardiovascular care. It's an important topic - not just for Cleerly, but for the healthcare industry and all the patients impacted by heart disease - and we're going...
4 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: January 28, 2022
Historically, our diagnostic approaches to patients with suspected heart disease have been restricted to the evaluation of patients with symptoms like chest pain and shortness of breath. Yet, these diagnostic methods fail for the >50% of individuals who...
